

**P&T Motion History
Insomnia Drugs (Sedative Hypnotics)**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
doxepin eszopiclone ramelteon suvorexant tasimelteon zaleplon zolpidem	Ask DERP to find evidence on untreated sleep apnea. We do not accept the scan as adequate due to the question of sleep agents used in sleep apnea. Motion: Johnson 2 nd : Sanderson	April 19, 2017	No	No	Passed unanimous
<ul style="list-style-type: none"> • Intermezzo • Edluar • Zolpimist 	After considering the evidence of safety, efficacy and special populations for the treatment of insomnia, I move that the newer sedative hypnotics be considered as two subclasses, benzodiazepine receptor agonists (eszopiclone, zaleplon, zolpidem and long acting zolpidem) and a non-benzodiazepine receptor agonist (ramelteon). The newer sedative hypnotics are safe and efficacious. The benzodiazepine receptor agonists can be subject to therapeutic interchange in the Washington preferred drug list for the treatment of insomnia, ramelteon cannot be substituted for other drugs in this class. At least one benzodiazepine receptor agonist must be preferred.	February 24, 2016	Yes Harvey Sanderson	Yes Smith Harvey	Passed